Fisher & Paykel Healthcare
(ASX:FPH) has released its half year results ending 30 September 2016.
The company says its NPAT rose 26% to NZ$78.2 million this half year. Also, its operating revenue was 12% higher at NZ$425.2 million, compared to the same time last year.
Fisher & Paykel also says it its revenue from consumables, which are used for non-invasive ventilation and surgical applications, grew by 35%.
The company’s managing director and CEO, Lewis Gradon, provided an upbeat outlook for FY17. Mr Gradon announced that the company upgraded its full year earnings guidance between NZ$165 million and NZ$170 million.
In regards to the company’s interim dividend, that has risen 23% to 8.25 cps, with full New Zealand imputation credit.
